As consumer interest in metabolic health, gut support and clean-label products accelerates, dietary fiber, like carob, ...

Claire Reed, from Aberdeen in Scotland, was prescribed Mounjaro in March after she was left 'fed up' of not fitting into her ...

Linda Yaccarino has a new job in a vastly different industry weeks after her exit as CEO of X, Elon Musk 's social discourse ...

GLP-1RAs were associated with lower risk for major adverse cardiovascular and cerebrovascular events in MGUS with type 2 diabetes.

Eris Lifesciences to leverage Novo Nordisk's exit and semaglutide patent expiry, with cartridge capacity and diabetes-focused ...

Coming off GLP-1 drugs doesn’t have to mean inevitable weight gain. Giulia Crouch asks doctors what you can do to keep it off ...

Novo Nordisk (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than ...

Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Aetna’s multi-year margin recovery is a top priority, and CVS is making progress through organizational realignment, ...

Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment ...

MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.